retinitis pigmentosa

Opus Initiates Gene Therapy Trial for MERTK Retinal Disease

Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited...

By cGxPwire Editor
January 28, 2026

Bio-Pharma

Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation

Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...

By cGxPwire Editor
November 9, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

retinitis pigmentosa

Opus Initiates Gene Therapy Trial for MERTK Retinal Disease

Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation